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The Efficacy of a Lateral Wedge Insole for Painful Medial 
Knee Osteoarthritis After Prescreening: A Randomized 
Clinical Trial
David T. Felson,1 Matthew Parkes,2  Suzanne Carter,2 Anmin Liu,3 Michael J. Callaghan,4 Richard Hodgson,5 
Michael Bowes,6 and Richard K. Jones3
Objective. Lateral wedge shoe insoles decrease medial knee loading, but trials have shown no effect on pain in 
medial knee osteoarthritis (OA). However, loading effects of insoles are inconsistent, and they can increase patel-
lofemoral loading. We undertook this study to investigate the hypothesis that insoles would reduce pain in preselect-
ed patients.
Methods. Among patients with painful medial knee OA, we excluded those with patellofemoral OA and those with 
a pain rating of <4 of a possible 10. We further excluded participants who, in a gait analysis using lateral wedges, did 
not show at least a 2% reduction in knee adduction moment (KAM), compared to wearing their shoes and a neutral 
insole. We then randomized subjects to lateral wedge versus neutral insole for 8- week periods, separated by an 
8- week washout. The primary outcome measure was knee pain (0–10 scale) during the past week, and secondary
outcome measures included activity pain and pain rated in the Knee Injury and Osteoarthritis Outcome Score ques-
tionnaire. We carried out mixed model analyses adjusted for baseline pain.
Results. Of 83 participants, 21 (25.3%) were excluded from analysis because of insufficient reduction in KAM. In 
the 62 patients included in analysis, the mean ± SD age was 64.2 ± 9.1 years, and 37.1% were women. Lateral wedge 
insoles produced a greater reduction in knee pain than neutral insoles (mean difference of 0.7 on 0–10 scale [95% 
confidence interval 0.1, 1.2]) (P = 0.02). Findings for secondary outcome measures were mixed.
Conclusion. In participants prescreened to eliminate those with patellofemoral OA and biomechanical nonre-
sponders, lateral wedge insoles reduced knee pain, but the effect of treatment was small and is likely of clinical sig-
nificance in only a minority of patients. Targeting patients may identify those who respond to this treatment.
INTRODUCTION
Approximately 12% of people age 60 and over have painful 
knee osteoarthritis (OA) (1). Rates of knee replacement have been 
rising in large part because of the failure of medical and rehabili-
tative treatments. New treatments for knee OA are badly needed.
Lateral wedge insoles placed inside shoes laterally shift load-
ing across the knee during walking. They reduce the load across 
the medial knee, where most affected individuals have either iso-
lated disease or disease combined with involvement of the patel-
lofemoral (PF) joint. Lateral wedge insoles reduce the external 
knee adduction moment (KAM), a measure of the load across the 
medial versus lateral compartments, by 5–6% (2,3). Unfortunately, 
in trials, lateral wedges have not demonstrated a reduction in knee 
pain, compared to neutral insoles. In a meta- analysis by Parkes 
et al (4), 8 randomized controlled trials comparing lateral wedge 
insoles to neutral insoles produced null results, and the effect size 
on pain reduction was 0.03 (95% confidence interval [95% CI] 
−0.18, 0.22). A subsequently published trial also produced neg-
ative findings (5).
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In 25% of patients, the wedge does not reduce medial load 
(6,7). Furthermore, OA in the PF joint may worsen as load is shifted 
laterally. We therefore hypothesized that if we selected individuals 
with painful medial compartment knee OA who showed a biome-
chanical response to wedge insoles and did not have painful PF 
OA, they would experience a reduction in knee pain with these 
insoles compared to neutral insoles.
Because the use of a shoe insole is a simple, low- cost inter-
vention, its efficacy in reducing pain could translate into a substan-
tial public health benefit and possibly into widespread use. Further, 
medial knee OA is highly prevalent not only in Western countries 
but in developing countries where knee replacement surgery is 
not widely available. We conducted a crossover trial testing a 5° 
lateral wedge insole, which is the same insole we and others pre-
viously tested (8).
PATIENTS AND METHODS
Recruitment and eligibility. Recruitment. This study 
was a randomized trial (registration no. ISRCTN55059760) that 
tested lateral wedge insoles and neutral insoles in persons with 
painful medial knee OA. The protocol was approved by National 
Research Ethics Service Committee North West (Preston, UK). 
Subjects were recruited from general practices and by way of 
advertisements in Manchester, UK from January 2016 through 
June 2017.
Inclusion criteria. We instituted the following eligibility criteria: 
ages 40–85 years; severity of overall knee pain (the primary out-
come measure) in the past week of ≥4 on a 0–10 grading scale, 
and Kellgren/Lawrence (K/L) (9) grade of 2–4 in the painful knee 
(as scored by a musculoskeletal radiologist) on a posteroanterior 
or anteroposterior radiograph obtained within the last 2 years 
that showed definite medial (but no definite lateral) narrowing. 
Patellofemoral OA had to be less severe than medial OA and 
could not have a K/L grade of ≥3. Additional inclusion criteria 
included medial joint line tenderness (with tenderness over the 
patella less severe than medial tenderness) upon examination 
by an experienced physical therapist (MJC), a stable medication 
regimen for 3 months, and a willingness to wear insoles in shoes 
for ≥4 hours daily.
Exclusion criteria. Subjects were excluded for the follow-
ing reasons: a history of high tibial osteotomy, other realign-
ment surgery, or knee replacement in the painful knee, knee ar-
throscopy within the last 6 months, or an intraarticular injection 
of either steroid or viscosupplementation in the affected knee 
within the past 3 months. People with the following disorders or 
conditions were also excluded: rheumatoid arthritis or other in-
flammatory arthritis, diabetic neuropathic pain or fibromyalgia, 
foot or ankle problems that contraindicated the use of load- 
modifying interventions in footwear, or severe coexisting med-
ical morbidities. Further exclusions included inability to walk 
unaided without a crutch, cane or walker, body mass index 
(BMI) ≥35 kg/m2, and current use of or need for foot orthoses. 
We also excluded those who were unable to retain information 
regarding study procedures or were unable to walk 100 meters 
without stopping. A secondary outcome measure was change 
in magnetic resonance imaging (MRI) features, and those with 
contraindications to MRI were also excluded, as were those 
with knee surgery planned within the next 6 months.
Evaluation and treatment. For eligible subjects, a gait 
laboratory appointment was made. At the time of this appoint-
ment, subjects were randomized remotely for the order of testing 
of insoles in their shoes (no insole, neutral insole, or lateral wedge 
insole). A 10- camera Qualisys ProReflex motion analysis system 
operating at 100 Hz and 2 Kistler force plates operating at 1,000 
Hz were used to measure kinematics and kinetics. Each subject 
participated in a minimum of 5 successful trials (defined as when 
a single foot contacted the force plate). The Calibrated Anatom-
ical Systems Technique marker set technique (10) was used (8). 
Retroreflective markers were mounted securely to participants’ 
shoes, with the foot modeled as a rigid segment. Ankle and knee 
joint centers were calculated as midpoints between the malleoli 
and femoral epicondyles, respectively. The hip joint center was 
calculated using the regression model from Bell et al (11), based 
on anterior and posterior superior iliac spine markers. Participants 
walked at self- selected speeds, which were similar across condi-
tions. Using an inverse dynamic approach Visual 3D (C- Motion), 
we calculated the first peak KAM normalized to a participant’s 
mass (Nm/kg) and averaged across the 5 trials. In addition, sub-
jects were asked about the comfort of each condition and whether 
they noted any immediate effect on knee pain.
A subject was characterized as a biomechanical responder 
if, for the study knee, there was a ≥2% reduction of their KAM 
with the lateral wedge insole compared to both that with their own 
shoe and that with the neutral insole. Biomechanical responders 
were eligible for the study. We chose a 2% reduction as it was 
above the minimal detectable difference in KAM (12) and was a 
reasonable approach to ensure biomechanical response.
Eligible subjects were randomized by a statistician who had 
no contact with study staff and created sealed opaque enve-
lopes for each study ID number, to be opened when a subject 
entered the study. The randomized allocation list used to cre-
ate the envelopes was a single- allocation computer- generated 
list of balanced permuted blocks with a block size of 6. Study 
staff were blinded with regard to block size. Subjects were 
randomized 1:1 to 1 of 2 treatment sequences (AB or BA) in 
a 2- period crossover trial. Each randomized participant was 
provided either a 5° lateral wedge insole (A) or a neutral insole 
(B), for 8 weeks, followed by an 8- week washout. Next, they 
switched to the other treatment for 8 weeks. The initial insole 
treatment was removed at the last visit of the assigned treatment 
period in order to prevent treatment contamination. Both insoles 
had a density of 70 Shore A.
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Participants attended the clinic for 5 visits: a screening visit 
(2 weeks prior to baseline), baseline visit (0 weeks), posttreat-
ment visit (8 weeks), post- washout visit/second baseline visit (16 
weeks), and second posttreatment visit (24 weeks). Participants 
were asked to wear insoles at least 4 hours per day but could 
wear them for as long as they wanted.
Bone marrow lesions (BMLs) appear on knee MRI in regions 
where excessive loading has produced bone damage. Medial 
lesions predominated in those with medial OA. BMLs in the PF 
joint shrank over 6 weeks when focal loading was reduced in 
that area (13), suggesting that BMLs may respond to unloading 
treatments. We evaluated subjects for change in BML volume in 
the medial joint. At baseline, patients underwent MRI of the study 
knee; this was repeated at 8 weeks, 16 weeks, and 24 weeks. 
Using a Philips Achieva 3.0T scanner, we obtained sagittal images 
using spectral attenuated inversion recovery fat suppression, with 
repetition time 4,300 ms, echo time 50 ms, field of view 16 × 24 
cm, matrix 212 × 220 pixels, slice thickness 3 mm with 0.3- mm 
gap, and bandwidth 621–655 Hz/pixel.
Outcome measures: pain. The primary prespecified 
symptom outcome measure was overall pain in the knee in the 
Figure 1. Disposition of the patients in the lateral wedge insole (LWI) trial. * = multiple imputation was used to estimate missing values for 
patients, accounting for a greater number of patients than completed the trial. NRS = numerical rating scale; BMI = body mass index.
past week, scored using a numerical rating scale (0–10) as per 
recommendations of the Initiative on Methods, Measurement, and 
Pain Assessment in Clinical Trials (IMMPACT) group (14). At base-
line, subjects were also asked to identify the activity that provoked 
the most knee pain and to score pain during this activity at each 
visit (15). Finally, we administered the Knee Injury and Osteoarthri-
tis Outcome Score (KOOS) questionnaire at each visit (16).
Outcome measures: structure. Technicians at Imorphics, 
who were blinded with regard to treatment assignment, manually 
segmented BML volumes in paired images from each patient’s 
knee. BMLs were outlined on each MRI slice and the volume 
integrated over all slices. For sagittal images, on which we based 
results, technicians segmented BMLs in the patella, femur, and 
tibia. The intraclass correlation coefficient for interobserver reliability 
for BML volume was 0.91 (P < 0.001) (13). The primary structural 
outcome measure was change in medial BMLs. We defined these 
as BMLs involving either the tibia medial to the cruciate ligaments 
or the femur medial to the notch, using regions derived from the 
Whole- Organ Magnetic Resonance Imaging Score (17).
Sample size. We aimed to detect a treatment effect size 
(Δ) of 0.4 SD with 80% power (2- sided alpha level 0.05). Based 
on a within- patient SD of 2.4 for overall pain in the past week 
(18) while testing a lateral wedge insole, this effect size repre-
sents a difference of 1 point on this knee pain rating scale and
translates to a sample size of 52 subjects completing the trial.
We assumed 10% loss to follow- up and aimed to randomize 58
subjects.
Statistical analysis. Our analysis followed an intent- to- 
treat approach. Multiple imputation by chained equations was 
used to correct estimates for bias due to missing data, assum-
ing data were missing at random. To assess the difference in 
treatment effects between the two insoles, we used maximum- 
likelihood mixed- effects multiple linear regression models. The 
primary analysis model used overall pain in the last week (mea-
sured at the end of each treatment visit) as the outcome measure, 
which was adjusted for baseline (pretreatment visit) pain scores. 
Using the baseline value as a covariate (the analysis of covariance 
approach) is a recommended methodology with less bias and 
greater power to detect differences (19). Participant identification 
was included as a random effect. To test for carryover effects, we 
included 3 additional covariates: a treatment term, a period term, 
and a treatment- by- period interaction term (the term testing for 
carryover). We ran a second analysis model identical to the first 
except that the period and treatment- by- period interaction terms 
were removed.
The same regression models were used to analyze the sec-
ondary outcome measures, using the same terms but replacing 
“overall knee pain during the past week” with the specific second-
ary outcome measures. In addition to evaluating the response to 
insoles on a continuous scale, we defined responders as those 
who achieved an accepted minimally important difference in 
overall knee pain of 1 on the 0–10 scale (20). We examined the 
percentage of trial participants who achieved responder status 
according to this definition, using the change in the pain score 
at the beginning of the period to the pain score at the end of the 
period.
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0.54 ± 0.17 0.54 ± 0.16 0.55 ± 0.17 0.01 (0.00, 0.02) 0.00­(−0.01,­0.02)
KAM­difference,­% – – – 1.98­(−0.07,­4.03) 0.64­(−2.12,­3.39)
Immediate pain† 2.86 ± 2.46 2.33­±­2.35 2.05 ± 2.09 −0.78­(−1.28,­−0.28) −0.27­(−0.77,­0.23)
Immediate comfort† 7.29 ± 1.74 7.10 ± 2.21 7.62 ± 1.77 0.35­(−0.18,­0.88) 0.22­(−0.32,­0.75)
Responders (n = 62)
KAM­difference,­
absolute value
0.50 ± 0.15 0.49 ± 0.15 0.46 ± 0.14 −0.04­(−0.04,­−0.03) −0.03­(−0.04,­−0.03)
KAM­difference,­% – – – −7.54­(−8.53,­−6.55) −6.56­(−7.69,­−5.42)
Immediate pain† 3.03­±­2.21 2.84 ± 2.06 2.48 ± 1.89 −0.28­(−0.57,­0.02) −0.18­(−0.48,­0.11)
Immediate comfort† 7.00 ± 1.87 7.32­±­1.94 7.44 ± 1.77 0.14­(−0.21,­0.49) 0.12­(−0.22,­0.47)
* KAM = knee adduction moment; 95% CI = 95% confidence interval.




Of the 83 participants who satisfied inclusion criteria and 
were evaluated in the gait laboratory (Figure 1), 62 were biome-
chanical responders. In this group, the mean reduction in KAM 
with lateral wedge insoles compared to neutral insoles was 6.6% 
and compared to their own shoes was 7.5% (Table 1). In contrast, 
21 participants (25.3%) were biomechanical nonresponders, and 
their mean KAM was 2% higher with the lateral wedge insoles 
than with their own shoes (Table 1). There were no differences 
between responders and nonresponders in immediate knee pain 
upon walking in the laboratory or in the comfort of their own 
shoes versus the lateral wedge inserts. Randomized participants 
were on average 64 years old, had a mean BMI of 28 kg/m2, 
and the majority were men (Table  2). Of the 62  randomized 
 participants, 59 completed the first treatment period and 56 
completed the second treatment period.
We found no significant evidence of carryover effects for 
any of the outcome measures of interest. When we examined 
our primary outcome measure, we found that patients reported 
less knee pain when randomized to receive lateral wedge insoles 
than when using neutral insoles (mean difference in pain score 
0.7 [95% CI 0.1, 1.2]; P = 0.02) (Figure  2 and Table  3). The 
pain during participants’ most painful nominated activity was 
also less severe during the period that they used lateral wedge 
insoles (Table  3). However, we did not find significant differ-
ences between neutral insole use and lateral wedge insole use 
in KOOS pain scores or other KOOS subscales. We found no 
effect of treatment on medial BML volume or on total BML vol-
ume in the knee (Table 3). Results from complete case analyses 
were similar.
During the period of active treatment with lateral wedge 
insoles, 28% of participants (16 of 57) achieved a minimally 
important improvement, and with neutral insoles, 22% (13 of 
58) experienced this level of improvement. The odds ratio for
achieving important improvement while using lateral wedges
versus neutral inserts was 1.35 (95% CI 0.58, 3.13) (P = 0.49).
Participants reported a mean ± SD insole usage time of 7.10 ±
2.72 hours/day at the end of the first treatment period and
7.80 ± 3.17 hours/day at the end of the second treatment
period.
During the trial, 7 participants experienced side effects lead-
ing to temporary (3 participants) or permanent (4 participants) 
treatment discontinuation. Of these instances, 4 occurred dur-
ing lateral wedge insole treatment and 3 during neutral insole 
 treatment. Of the 2 participants who discontinued treatment 
with lateral wedge insoles, 1 had calf pain at night and the other 
experienced worse knee pain. Of the 2 participants who stopped 
using neutral insoles, 1 developed a toe blister and the other had 
worsening knee pain.
DISCUSSION
In this trial, we prescreened subjects for select biomechani-
cal responses to lateral wedge insoles. When we excluded those 
who either had PF involvement or failed to show biomechanical 






Age, years 64.18 ± 9.10 65.86­±­10.03
BMI, kg/m2 28.21­±­3.44 28.56­±­3.99
Women, no. (%) 23­(37.10) 9 (42.86)
HADS anxiety score† 12.17 ± 2.24 12.48 ± 1.57
HADS depression 
score†
9.10 ± 1.24 8.33­±­0.97
Overall knee pain 
during past week 
(0–10 range) 
5.26­±­1.63 5.24 ± 1.87
Pain during nominated 
activity (0–10 range)
6.18 ± 1.54 6.05 ± 1.66
KOOS pain subscale 
score (0–100 range)‡
55.20­±­13.45 58.07 ± 12.07
K/L grade of studied 
knee, no. (%)
Grade 2 17 (27.4) –
Grade­3 37­(59.7) –
Grade 4 8 (12.9) –
* Except where indicated otherwise, values are the mean ± SD. BMI =
body mass index; K/L = Kellgren/Lawrence.
† Hospital Anxiety and Depression Scale (HADS) scores ranged
from 0 to 21, with higher scores (>11) indicating either anxiety or
depression.
‡ Knee Injury and Osteoarthritis Outcomes Scores (KOOS) ranged
from 0 to 100, where 100 represents no pain/difficulty.
Figure 2. Crossover change in overall knee pain during the past 
week, assessed based on a numerical rating scale (NRS) of 0–10. 
Blue lines indicate lateral wedge insole, yellow lines indicate neutral 
insole, and broken lines indicate the washout period. Values are the 
mean and 95% confidence interval.
responses to lateral wedge insoles, we detected a small effect 
of these insoles on pain reduction that was missed in previous 
trials in which there was no prescreening. However, most partic-
ipants in the trial did not experience a level of improvement that 
would qualify as minimally important based on accepted thresh-
olds. While this trial suggests an approach to detect efficacy of 
this treatment, the efficacy was not sufficient to recommend this 
treatment or the screening approach we used. In this case, we 
may have found a treatment that shows statistical significance 
without clinical significance.
The small treatment effect we found may account for the 
lack of consistency across outcome measures. While the lat-
eral wedge insole reduced knee pain based on our primary out-
come measure (knee pain during the past week) and also led to 
pain reduction in the patient’s nominated most painful activity, 
it did not significantly reduce pain or self- reported function that 
was assessed using the KOOS survey, an expanded version of 
the Western Ontario McMaster Universities Osteoarthritis Index 
(WOMAC) (21). We have reported that the WOMAC is not as 
sensitive to change as are global questions about knee pain (15), 
which may partially explain the lack of effect. However, this lack 
of effect also suggests that the treatment effect was modest. 
For the primary  outcome  measure, the effect size calculated as 
a standardized response mean was 0.30. This effect is com-
parable to that found for nonsteroidal antiinflammatory drugs 
versus acetaminophen in OA pain treatment (22). While a vali-
dated estimate of minimally important improvement (20) for our 
primary outcome measure was 1.0, the mean difference in pain 
reduction between the lateral wedge and neutral insole periods 
of treatment was only 0.7.
Our screening process utilized a gait laboratory to iden-
tify participants who had a biomechanical response to wedge 
insoles. Such laboratory evaluations are expensive and may 
not be widely available. Clinical screening protocols could be 
developed that might identify, with high probability, those likely 
to respond. We have tried to develop such a protocol without 
success (23), and other efforts are needed. While the KAM 
measures the medial versus lateral load, another factor affecting 
medial joint loading is the knee flexion moment. We have previ-
ously reported that the lateral wedge insole used in this study 
does not affect this moment (24).
Once PF OA is ruled out by a simple physical examination, 
given the low cost and benign safety profile of these wedges, 
it might be argued that treating patients with these insoles is a 
reasonable clinical strategy, rather than seeking a gait laboratory 
evaluation. Even so, the treatment effect is likely to be small, and 
only a few patients may experience substantial benefit. Could the 
effect of lateral wedge insoles have been similar to those seen 
in previous trials that used the WOMAC or KOOS as outcome 
measures? In two large studies using variable stiffness shoes or 
Table 3. Comparison between lateral wedge insole and neutral insole after 8- week treatment*
Outcome
Posttreatment adjusted mean (95% CI) Difference between treat-
ments, 
mean (95% CI)Lateral wedge insole Neutral insole
Pain during past week† 4.16­(3.69,­4.62) 4.85 (4.42, 5.28) 0.70 (0.12, 1.27)‡
Pain during nominated 
activity†
4.80­(4.30,­5.31) 5.77 (5.28, 6.26) 0.97­(0.32,­1.61)§
KOOS score¶
Pain subscale 60.66 (57.21, 64.11) 58.82 (55.67, 61.96) −1.84­(−6.31,­2.62)
Symptoms subscale 60.64­(57.59,­63.70) 59.41 (56.40, 62.42) −1.23­(−5.11,­2.65)
Activities of daily living 
subscale
66.29­(63.15,­69.44) 65.01 (61.88, 68.14) −1.28­(−5.19,­2.62)
Sports and recreation 
subscale
43.57­(39.46,­47.67) 42.21­(37.56,­46.86) −1.36­(−6.97,­4.26)
Quality of life subscale 44.18­(40.62,­47.73) 44.09­(40.80,­47.38) −0.09­(−4.64,­4.47)















* Pain ratings and other scores were adjusted for the baseline value of the relevant outcome measure, which was the
same for both treatment groups. 95% CI = 95% confidence interval; KOOS = Knee Injury and Osteoarthritis Outcomes
Scores; BML = bone marrow lesion.
† Lower scores represent pain reduction.
‡ P = 0.02
§ P = 0.003
¶ Higher scores represent pain reduction.
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lateral wedge insoles (5,18), authors used the same global knee 
pain measure and found no effect of treatment (versus control) 
on pain.
Osteoarthritis is challenging to treat because it combines 
mechanopathology with an inflammatory response to joint 
injury, both of which contribute to pain and disease progres-
sion. It has been unclear whether nonsurgical treatments tar-
geting pathomechanics were likely to be major elements of the 
treatment regimen. Knee brace adherence is poor, for example. 
Our findings offer modest promise for a simple, inexpensive 
treatment. Further refinement of the treatment with use of spe-
cific shoes or increases in the degree of wedging may increase 
efficacy.
We and others have reported that biomechanical response 
to lateral wedge insoles is variable (24–26). Although the reasons 
are unclear, one study suggests that stiffness in feet and ankles 
in some individuals may prevent the lateral ankle eversion that is 
necessary for knee loading to change with this treatment (25). 
While lateral wedge insoles are thought to be safe treatments, 
their use occasionally generates reports of discomfort in the foot 
(22) and may cause back pain (20). In the present study, we did
not find major safety concerns, and no one discontinued treat-
ment due to back pain.
In this crossover trial, we sought to evaluate the effect of lat-
eral wedge insoles. Crossover trials permit the testing of treat-
ments more efficiently than parallel design trials and make it easier 
to detect modest effects of treatments.
In summary, we found, for the first time, that lateral wedge 
insoles may be modestly effective in reducing pain in patients with 
medial knee OA. However, the treatment effect was small and 
most treated patients did not achieve conventional levels of min-
imally important response. Future modifications of the screening 
strategy or treatment might offer greater levels of efficacy.
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